The Council of Scientific and Industrial Research has started the trials of anti-leprosy drug trials against COVID-19. The drug trial is to be conducted with the help of Mycobacterium MW.
Highlights
- The Mycobacterium MW is a heat killed bacteria.
- It is to be tried on different COVID-19 patients.
- The drug trial was approved by the Drug Controller General of India.
- One particular strain of bacteria called the Mycobacterium MW is to be tried on several COVID-19 patients.
- The drug has already proved its effectivity against leprosy.
- The CSIR is also trying phytopharmaceuticals
Phytopharmaceuticals
- The Phytopharmaceuticals are herbal medicines.
- They contain one or more plant products as Active Ingredients.
- Phytopharmaceuticals are preferred to synthetic drugs as their benefit-risk ratios are higher.
What is Mycobacterium MW?
- Mycobacterium MW is a strain of mycobacterium.
- It is a non-pathogenic, non-specific immune potentiating, rapidly growing atypical mycobacterium.
- This strain of bacteria shares a common T and B cell determinants with Mycobacterium tuberculosis and Mycobacterium leprae.
- The heat killed bacteria induces T-cell responses.
- This induces the responses of the cells against tumor cells as well.
About the Trial
- Along with CSIR Gujarat based pharma-giant Cadila Pharmaceuticals will also join the Mycobacterium trial.
- The hospitals that are to participate in the trial includes AIIMS Delhi, AIIMS Chandigarh and AIIMS Bhopal.
No comments:
Post a Comment